The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations
- 29 October 2010
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 42 (6), 966-974
- https://doi.org/10.1002/mus.21808
Abstract
In this study we used the 6-minute walk distance (6MWD) to characterize ambulation over time in Duchenne/Becker muscular dystrophy (DBMD). The 6MWD was assessed in 18 boys with DBMD and 22 healthy boys, ages 4–12 years, over mean [range] intervals of 58 [39–87] and 69 [52–113] weeks, respectively. Height and weight increased similarly in both groups. At 52 weeks, 6MWD decreased in 12 of 18 (67%) DBMD subjects (overall mean [range]: 357 [125–481] to 300 [0–510] meters; Δ −57 meters, −15.9%), but increased in 14 of 22 (64%) healthy subjects (overall mean [range]: 623 [479–754] to 636 [547–717] meters; Δ +13 meters, +2.1%). Two DBMD subjects lost ambulation. Changes in 6MWD depended on stride length and age; improvements usually occurred by 7–8 years of age; older DBMD subjects worsened, whereas older healthy subjects were stable. The 6MWD changes at 1 year confirm the validity of this endpoint and emphasize that preserving ambulation must remain a major goal of DBMD therapy. Muscle Nerve, 2010Keywords
This publication has 30 references indexed in Scilit:
- Emerging genetic therapies to treat Duchenne muscular dystrophyCurrent Opinion in Neurology, 2009
- T.P.3.05 Reproducibility and correlation of pretreatment outcome measures in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD)Neuromuscular Disorders, 2009
- Gait pattern in Duchenne muscular dystrophyGait & Posture, 2009
- T.O.4 Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adultsNeuromuscular Disorders, 2008
- Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophyNeuromuscular Disorders, 2007
- Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyThe Journal of Pediatrics, 2006
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- The Dystrophin Glycoprotein ComplexCirculation Research, 2004
- Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophyPediatric Neurology, 1996
- Duchenne Muscular DystrophyAmerican Journal of Physical Medicine & Rehabilitation, 1995